• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

    7.620 +0.070 (+0.93%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 32,579
    Open 7.530
    Bid (Size) 7.620 (2)
    Ask (Size) 7.730 (3)
    Prev. Close 7.550
    Today's Range 7.324 - 7.750
    52wk Range 3.210 - 10.69
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
    From Coya Therapeutics, Inc.
    Via Business Wire
    7 Biotech Stocks to Put on Your Breakthrough Radar
    Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
    Via InvestorPlace

    Performance

    YTD
    +9.48%
    +9.48%
    1 Month
    -9.39%
    -9.39%
    3 Month
    -16.72%
    -16.72%
    6 Month
    +45.14%
    +45.14%
    1 Year
    +57.76%
    +57.76%

    More News

    Read More
    EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
    Via Benzinga
    Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
    From Coya Therapeutics, Inc.
    Via Business Wire
    COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
    Via InvestorPlace
    Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
    From Coya Therapeutics, Inc.
    Via Business Wire
    COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics
    Via Talk Markets
    Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in BTIG Fireside Discussion
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
    Via Benzinga
    Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
    From Coya Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.